Literature DB >> 27231859

Idiopathic Pulmonary Fibrosis: Epidemiology, Clinical Features, Prognosis, and Management.

Joseph P Lynch1, Richard H Huynh1, Michael C Fishbein2, Rajan Saggar1, John A Belperio1, S Sam Weigt1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic interstitial lung pneumonia associated with the histologic pattern of usual interstitial pneumonia (UIP). Although UIP is a distinct histologic lesion, this histologic pattern is not specific for IPF and can also be found in other diseases (e.g., connective tissue disease and asbestosis). Clinical features of IPF include progressive cough, dyspnea, restrictive ventilatory defect, and progressive fibrosis and destruction of the lung parenchyma. IPF is rare (13-42 cases/100,000), and primarily affects older adults (>50 years of age). The diagnosis of IPF often requires surgical lung biopsy, but the diagnosis can be affirmed with confidence in some patients provided the results of computed tomographic (CT) scans and clinical features are consistent. The clinical course is variable, but inexorable progression (typically over months to years) is typical. Mean survival from the onset of symptoms approximates 3 to 5 years. Medical treatment is only modestly effective, primarily by slowing the rate of disease progression. Lung transplantation is the best therapeutic option. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27231859     DOI: 10.1055/s-0036-1582011

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  7 in total

1.  Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis.

Authors:  Wan-Li Zuo; Jie-Min Zhao; Ji-Xiong Huang; Wei Zhou; Ze-Hong Lei; Yan-Ming Huang; Yan-Fen Huang; Hai-Gang Li
Journal:  Biomed Rep       Date:  2016-12-29

2.  Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis.

Authors:  Rong Zhang; Zhanshuai Song; Yan Guan; Juan Zhang; Jianfang Zou; Yingxin Sun; Hua Shao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

3.  Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis.

Authors:  Carlos Machahua; Ana Montes-Worboys; Lurdes Planas-Cerezales; Raquel Buendia-Flores; Maria Molina-Molina; Vanesa Vicens-Zygmunt
Journal:  Respir Res       Date:  2018-11-08

4.  Investigation of circular RNAs and related genes in pulmonary fibrosis based on bioinformatics analysis.

Authors:  Liteng Yang; Xin Liu; Ning Zhang; Lifang Chen; Jingyi Xu; Wencheng Tang
Journal:  J Cell Biochem       Date:  2019-02-14       Impact factor: 4.429

Review 5.  The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.

Authors:  Lucy A Murtha; Michael J Schuliga; Nishani S Mabotuwana; Sean A Hardy; David W Waters; Janette K Burgess; Darryl A Knight; Andrew J Boyle
Journal:  Front Physiol       Date:  2017-10-12       Impact factor: 4.566

6.  Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study.

Authors:  Sang Hoon Lee; Jong Sun Park; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Woo Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Moo Suk Park
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

7.  Multiple Traditional Chinese Medicine interventions for idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis of overview.

Authors:  Hao-Yang Zhang; Li-Jian Pang; Xiao-Dong Lv; Chuang Liu; Ming-Hua Nan
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.